Developer of an eutectic ionic liquid designed to minimize the pervasive use of systemic drugs for the treatment of dermal diseases and symptoms. Cage Bio is based in San Carlos, CA. Its last reported valuation was $125 million in Jun 2019. It has raised $57.6 million across 3 recorded rounds; the latest was an $11 million early-stage round in Apr 2024.
Last reported valuation
$125.0M
Oct 2026
Priced at
—
Total raised
$57.6M
Last round
Early Stage VC
Apr 2024
No prints on record
No secondary trades in Cage Bio shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Cage Bio with a free account
·Watch Cage Bio: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Cage Bio stock.
